News - Generics
Generic Lipitor recall update: Millions continue using Ranbaxy atorvastatin ...
29 November 2012
Despite a recall, millions of people may continue taking a generic form of Lipitor that might contain specks of glass. Ranbaxy Pharmaceuticals issued the recall at the retail level Friday, directing pharmacies not to dispense contaminated lots of the ...
Click on the link to read the full article at WPTV (This link will open in a new window)More states likely to instruct doctors to prescribe generic drugs; but ...
29 November 2012
More states are likely to issue directions to the doctors in the public health institutions to prescribe the generic drugs, as part of the activities to promote generic drugs in the country. However, there is no legislation likely now to make it ...
Click on the link to read the full article at pharmabiz.com (This link will open in a new window)Cadence Pharmaceutical's Patent Settlement Bolsters My Buy Rating
28 November 2012
Cadence Pharmaceuticals (CADX) is up about 6% today on the announcement that it has entered into a settlement with Perrigo (PRGO) on patent litigation regarding Ofirmev is a positive. Uncertainty over the patent situation of Ofirmev has been a dark ...
Click on the link to read the full article at Seeking Alpha (This link will open in a new window)Bill to get lifesaving generic drugs to developing world hangs on a few Tory votes
28 November 2012
Supporters of a private-member's bill that would make more cheap generic versions of lifesaving drugs available to the world's poor are fearful that the Conservative government is preparing to stop the proposed legislation in its tracks. Bill C-398 ...
Click on the link to read the full article at Globe and Mail (This link will open in a new window)Bill to get lifesaving generic drugs to world's poor hangs on a few ...
28 November 2012
Supporters of a private-member's bill that would make more cheap generic versions of lifesaving drugs available to the world's poor are fearful that the Conservative government is preparing to stop the proposed legislation in its tracks. Bill C-398 ...
Click on the link to read the full article at Globe and Mail (This link will open in a new window)Generic OxyContin gets OK
28 November 2012
But the generics will use the same older, "easy to tamper with" formulation in the now discontinued Oxy-Contin, doctors who treat patients with chronic pain or addiction wrote in a letter to federal health minister Leona Aglukkaq Nov. 19. "If there ...
Click on the link to read the full article at Ottawa Citizen (This link will open in a new window)US price hikes on branded drugs far outpace 2012 inflation
28 November 2012
There is great incentive for companies like Express Scripts to increase generic usage, not only to save client's money but because the profit margin is higher on cheap generics than with expensive branded drugs. Pharmacy benefit managers, or PBMs, ...
Click on the link to read the full article at Reuters UK (This link will open in a new window)Canadians: write to Parliament about keeping generic pharma available to poor ...
27 November 2012
This is essentially important discussion over the fate of a law that would allow a measured approached for the production of life saving generic medicines within Canada. These generics are life saving in the sense that with this law in place, meds that ...
Click on the link to read the full article at Boing Boing (This link will open in a new window)Health Canada approves generic OxyContin; doctors fear increased abuse of ...
27 November 2012
Health Canada has swiftly approved six generic copies of the widely abused painkiller OxyContin, despite urgings from some of the country's leading pain doctors and researchers to delay approval in the name of ?patient and public safety.? The first ...
Click on the link to read the full article at Vancouver Sun (This link will open in a new window)Teva Won't Sell Gilead Generics Until June or Ruling
27 November 2012
Teva Pharmaceuticals agreed to delay the introduction of generic versions of two Gilead Sciences Inc. (GILD) HIV drugs until June if a judge hasn't ruled in its favor by then in a patent case brought by Gilead. U.S. District Judge Richard Sullivan in ...
Click on the link to read the full article at Bloomberg (This link will open in a new window)
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
